A BioSpace report on February 3, 2026, states Novo Nordisk's next-gen obesity drug beats Wegovy on blood sugar control in Phase III trials.2
Novo Nordisk's CagriSema, a weekly injection combining semaglutide and cagrilintide, is in Phase 3 with early data suggesting greater weight loss than Wegovy, potentially over 20%, and improved glucose control.1
The FDA approved the oral Wegovy pill (25 mg semaglutide) on December 22, 2025, based on OASIS 4 Phase 3 trial showing 14-17% average weight loss over 64 weeks.123
This approval marks the first high-dose oral GLP-1 for obesity, launching in early January 2026 in the US, comparable to injectable Wegovy's efficacy.12
Sources:
1. https://www.juiceboxpodcast.com/blog/2026/1/4/the-wegovy-pill-arrives
2. https://www.biospace.com/press-releases/best-semaglutide-options-for-2026-new-oral-wegovy-pill-approved-by-fda-as-patients-compare-injectable-and-compounded-access-pathways
3. https://www.privatedoc.com/resource-library/weight-loss/whats-new-weight-loss-2026